Maximise yield in your chemically-defined cell culture media

Introducing Short AE-IGF-1 growth factor additive for cell culture from CellRx

CellRx is supplying a proprietary AE version of the IGF-1 analogue, Short AE-IGF-1, that is well-characterised, pure and liquid stable. CellRx Short AE-IGF-1 is a competitively-priced, high-performance alternative to human insulin, LONG®R3IGF-1 and IGF-1 for use in technical research, large-scale commercial cell culture and bioprocessing.

Homepage

Maximum Performance

In multiple case studies Short AE-IGF-1 matched or performed significantly better than competing products both in productivity (recombinant protein production) and cell viability (reduction in apoptosis).

Homepage
Productivity vs. Insulin (Per.C6)
Short AE-IGF-1
LONG R3 IGF-1
Insulin
0%
More IgG production over insulin
Download Case Study
Productivity vs. IGF-1 (CHO)
Short AE-IGF-1
LONG R3 IGF-1
IGF-1
0%
More IgG production over IGF-1
Download Case Study
Viability vs. IGF-1 (CHO)
Short AE-IGF-1
LONG R3 IGF-1
IGF-1
0%
More viable cells over IGF-1
Download Case Study

Unbeatable Value

At an unbeatable cost price, CellRx Short AE-IGF-1 offers maximum performance at the best value for both small and large volume consumers

LONG R3 IGF-1

$25,000 /0.5g
  • Leading Suppliers

Short AE-IGF-1

$8,000/0.5g
  • CellRx

Insulin

$17,000/50g
  • Leading Suppliers

CellRx Short AE-IGF-1 price comparison is shown against published catalogue rates for 500mg of LONG R3 IGF-1 and 50g of Insulin.
(Reference insulin potency taken as 1/100th of IGF-1)

2-3x

For larger (bulk) volumes Short AE-IGF-1 offers at least 2-3x better value than the competing products.

Proven Science

Human insulin-like growth factor I (IGF-1) is a basic polypeptide of MW 7649 comprising 70 amino acid residues of which 6 are cysteine residues forming 3 disulfide bonds. The peptide has a high homology with insulin and belongs to the proinsulin family. IGF-1 has been shown to be a growth factor for cells of mesenchymal origin.

Short AE-IGF-1 is a derived analogue of IGF-1 where a key residue on the IGF-1 structure is linked to an N-terminal fusion partner.

The result is a molecule that:

  1. Significantly reduces the binding of the growth factor to the IGF-1 binding proteins present in cell culture.
  2. Increases refolding efficiency of the protein.
  3. Facilitates high-yield expression and recovery of the target protein.

Short AE-IGF-1, an analogue and superior alternative to IGF-I, is a highly potent and effective animal-free recombinant growth factor specifically engineered for use in industrial cell culture.

All cells that have a functional Type 1 IGF receptor will respond to Short AE-IGF-1. This includes commercially available cell lines such as CHO, PER.C6, BHK, HEK 293, Embryonic stem cells, mesenchymal stem cells, hematopoietic stem cells, broblasts, and hybridomas.

Short AE-IGF-1 is supplied as a stable soluble product and is available as a 1-2mg/ml clear liquid formulation in 100mM acetic acid that can be added directly into cell culture media without any further handling or risk of influence on cell culture pH and osmolality.

With CHO cells increasingly being used in the production of biotherapeutics in serum-free media formulations growth factors such as insulin proved crucial for long-term growth and proliferation of cell lines in serum-free media formulations. As insulin is a key component, as a therapeutic for the treatment of diabetes, this has led to supply and availability issues for cell culture users.

In contrast, Short AE-IGF-1 is a dedicated raw material manufactured exclusively for the cell culture market and provides a consistent and reliable growth factor. It is produced in an Escherichia coli expression system without the use of animal-derived components. Cells are cultivated in a propriety fed-batch process using fully dened animal free media components. Recombinant Short AE-IGF-1 (MW 7.85kDA) is refolded into a stable tertiary structure and further purified by chromatographic processes. Each batch is supplied with a detailed certificate of analysis.

Short AE IGF-1 produced in this way is more stable; exhibits at least 100x more potency and; can be produced at a lower cost compared to recombinant human insulin and natively produced IGF-1 making it a highly-competitive market alternative.

In addition, Short AE-IGF-1 exhibits, at minimum, an equivalent stability and can be produced at a greatly reduced cost compared to LONG R3IGF-1. This allows this Short AE-IGF-1 to be used at concentrations that allow equivalent potency while retaining a significant production cost advantage.

Quality Assurance

Commercial-grade growth factor designed for scale

100%
Regulatory compliant, GMP and 100% animal-free

Short AE-IGF-1 is manufactured in a proprietary E. coli fermentation process under ISO 13485 conditions, conforms to all FDA QSR guidelines, is certified 100% animal free to a tertiary level and has requisite CofA’s. The manufacturing plant is audited by major US, European and Japanese biopharmaceutical companies.

A certificate of origin is available on request.

Comprehensive risk management and supply security

Short AE-IGF-1 inventory is built in advance to handle the fluctuating needs of customers and is available for immediate shipment. A comprehensive risk management strategy includes an inventory surplus equal to 2 year’s forecast demand and is maintained in secured storage facilities at relevant sites. For a complete overview of the risk management strategy, please contact your CellRx sales representative.

Broad use across cell lines

Short AE-IGF-1 has been used with numerous cell types including CHO, vaccine-producing cell lines, fibroblasts and stem cells.  All cells that have a functional Type 1 IGF receptor will respond to Short AE-IGF-1. This includes commercially available Cell lines such as CHO, PER.C6, BHK, HEK 293, Embryonic stem cells, mesenchymal stem cells, hematopoietic stem cells, fibroblasts, and hybridomas.

User-friendly formulations for greater flexibility

Short AE-IGF-1 is supplied as a stable soluble product that can be added directly into cell culture media without any further handling or risk of influence on cell culture pH and osmolality. Liquid, Short AE-IGF-1, in original unopened vial is stable for at least 4 years when stored at 2-8°C.

Produced under strict FDA, EMA and GMP quality guidelines
Homepage

Order Now

CellRx Short AE-IGF-1 is available for immediate world-wide shipping.
Please use the order request form below to initiate your order or contact us for any questions or purchase enquiries

Order Request

Select Product

Contact Details

Pricing

Cat. # Pack Size Price (US $)
8000 100µg Evaluation*
8010 10mg $400
8011 100mg $2,500
8012 500mg $8,000
8013 1,000mg $13,000
8014 Bulk Custom*

*Contact us for bulk pricing options and evaluation samples.

Store at 2-8°C

Storage and handling of the product should be maintained between 2-8°C for optimum stability and efficacy.

Here to help!

Do give us a call or email us for more information about the product and purchase enquiries.

Tel: + 44 1223 364 412
sales@cellrxbio.com

Services

CellRx has excellent technical expertise in the area of bioprocessing and can offer a range of services to the bioprocessing industry.

Learn more

About CellRx

CellRx Limited (CellRx) is a manufacturer and supplier of growth factors that serve the technical research and bioprocessing markets. Our first product to market is Short AE-IGF-1, a well-characterized, high potency, competitively priced alternative to insulin and other insulin-like analogues. CellRx also offers a range of services to the bioprocessing industry including GMP contract manufacturing, bioprocess development and optimization.

Learn more

CellRx Short AE-IGF-1 is available for laboratory research and large-scale in-vitro biopharmaceutical manufacturing use only. Not for diagnostic or therapeutic use.

Short™ AE-IGF-1 is a registered trademark of CellRx Ltd. (Synonyms include AE-IGF-1, RhShort AE-IGF-1, Short IGF). LONG® is a registered trademark of Novozymes Biopharma AU.